Summary of this trial

This Phase 1/Phase 2 trial in patients with Multiple Myeloma is being sponsored by Karyopharm Therapeutics, Inc. 116 individuals will be dosed with one or more of the following: KPT-8602. Trial dates are from 1st January 2016 to 1st June 2017. The study is currently active, not recruiting.

View trial on source site